Clinical Trials Browser

Advanced Malignancies

Lymphoma, Non-Hodgkin, Recurrence

Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Biliary Tract Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Head and Neck Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Multiple Pulmonary Nodules

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

Advanced Solid Tumor

Esophageal Squamous Cell Carcinoma

Locally Advanced and Metastatic Solid Tumors

Mid-low Rectal Cancer

Stomach Neoplasms

Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Clinical Trials

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma

SITISVEAL

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

FRONT-1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

HESTIA

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

PPIO-004-EC001

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

A Benefit Population Atlas of nICT Versus nCT for LAGC

neoCHANCE-1

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

TALENT